Nonresponse and Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Treatment

被引：9

作者：

Chuluunbat, Tsengelmaa ^{[1
]}

Chan, R. V. Paul ^{[2
]}

Wang, Nan-Kai ^{[3
,4
]}

Lien, Reyin ^{[4
,5
]}

Chen, Yen-Po ^{[3
,4
]}

Chao, An-Ning ^{[3
,4
]}

Chen, Kuan-Jen ^{[3
,4
]}

Chen, Tun-Lu ^{[3
,4
]}

Hwang, Yih-Shiou ^{[3
,4
]}

Lai, Chi-Chun ^{[3
,4
]}

Wu, Wei-Chi ^{[3
,4
]}

机构：

[1] Natl Ctr Maternal & Child Hlth, Dept Ophthalmol, Ulaanbaatar, Mongolia

[2] Univ Illinois, Dept Ophthalmol & Visual Sci, Illinois Eye & Ear Infirm, Chicago, IL USA

[3] Chang Gung Mem Hosp, Dept Ophthalmol, Taoyuan 333, Taiwan

[4] Chang Gung Univ, Coll Med, Taoyuan, Taiwan

[5] Chang Gung Mem Hosp, Dept Pediat, Taoyuan, Taiwan

来源：

OPHTHALMIC SURGERY LASERS & IMAGING RETINA | 2016年 / 47卷 / 12期

关键词：

ENDOTHELIAL GROWTH-FACTOR; BEVACIZUMAB MONOTHERAPY; LASER TREATMENT; PRETHRESHOLD; CRYOTHERAPY; THRESHOLD; INJECTION; THERAPY;

D O I：

10.3928/23258160-20161130-03

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

BACKGROUND AND OBJECTIVE: To evaluate the surgical outcome of type 1 retinopathy of prematurity (ROP) after intravitreal ranibizumab (IVR) (Lucentis; Genentech, South San Francisco, CA) treatment. PATIENTS AND METHODS: This was a prospective case series. Premature infants with treatment-requiring ROP who received IVR injections from 2013 to 2015 were included. RESULTS: Twenty-two eyes of 12 children were included in the study. Complete resolution of ROP after a single IVR was noted in 73% of eyes. Retreatment was needed in 27% of eyes due to nonresponse to IVR (18%) or recurrence of ROP (9%). After that, all treated eyes (100%) demonstrated regressed ROP with attached retina. The median visual acuity was 0.3 LogMAR (range: 0 LogMAR to 0.8 LogMAR) with a mean follow-up of 25.2 months +/- 6.8 months. CONCLUSIONS: IVR is effective and well-tolerated for patients with treatment-requiring ROP. However, nonresponse to IVR or recurrence of ROP after IVR was noted in 27% of treated eyes and required additional treatment.

引用

页码：1095 / 1105

页数：11

共 34 条

[1] Pharmacokinetics of intravitreal ranibizumab (Lucentis)
Bakri, Sophie J.
Snyder, Melissa R.
Reid, Joel M.
Pulido, Jose S.
Ezzat, Mohamed K.
Singh, Ravinder J.
[J]. OPHTHALMOLOGY, 2007, 114 (12) : 2179 - 2182
[2] Primary Intravitreal Ranibizumab for High-Risk Retinopathy of Prematurity
Baumal, Caroline R.
Goldberg, Roger A.
Fein, Jordana G.
[J]. OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2015, 46 (04) : 432 - 438
[3] Introduction: Understanding the Role of Angiogenesis and Antiangiogenic Agents in Age-Related Macular Degeneration
Bressler, Susan B.
[J]. OPHTHALMOLOGY, 2009, 116 (10) : S1 - S7
[4] INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT FOR RETINOPATHY OF PREMATURITY Comparison Between Ranibizumab and Bevacizumab
Chen, San-Ni
Lian, Iebin
Hwang, Ya-Chi
Chen, Yi-Hsing
Chang, Yao-Chung
Lee, Kun-Hsien
Chuang, Chih-Chun
Wu, Wei-Chi
[J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2015, 35 (04): : 667 - 674
[5] A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years - Part 2. Refractive outcome
Connolly, BP
Ng, EYJ
McNamara, JA
Regillo, CD
Vander, JF
Tasman, W
[J]. OPHTHALMOLOGY, 2002, 109 (05) : 936 - 941
[6] Safety Implications of Vascular Endothelial Growth Factor Blockade for Subjects Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Therapies
Csaky, Karl
Do, Diana V.
[J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 2009, 148 (05) : 647 - 656
[7] Refractive Outcomes Following Bevacizumab Monotherapy Compared With Conventional Laser Treatment A Randomized Clinical Trial
Geloneck, Megan M.
Chuang, Alice Z.
Clark, W. Lloyd
Hunt, Michael G.
Norman, Alan A.
Packwood, Eric A.
Tawansy, Khaled A.
Mintz-Hittner, Helen A.
[J]. JAMA OPHTHALMOLOGY, 2014, 132 (11) : 1327 - 1333
[8] Good WV, 2003, ARCH OPHTHALMOL-CHIC, V121, P1684
[9] Managing patients treated with bevacizumab combination therapy
Gordon, MS
Cunningham, D
[J]. ONCOLOGY, 2005, 69 : 25 - 33
[10] Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity
Hoerster, Robert
Muether, Philipp
Dahlke, Claudia
Mehler, Katrin
Oberthuer, Andre
Kirchhof, Bernd
Fauser, Sascha
[J]. ACTA OPHTHALMOLOGICA, 2013, 91 (01) : e74 - e75

← 1 2 3 4 →